Guardant Health vs Grail
GH and GRAL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GH and GRAL compare
Guardant Health is the larger company, worth 3.7 times as much as Grail ($24.0B against $6.4B).
Guardant Health grew revenue faster over the last twelve months (42.7% versus 23.1% for Grail).
Guardant Health keeps more of each dollar of sales as profit, with a net margin of −38.3% compared with −237% at Grail.
Grail scores higher on the StockData Score (10 against 9 for Guardant Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GH | GRAL |
|---|---|---|
| Size and price | ||
| Market cap | $24.0B | $6.4B |
| Share price | $178.80 | $143.43 |
| Change, 1 year | 147% | 68.3% |
| Change, 5 years | 62.3% | – |
| Beta (5Y) | 1.61 | 2.50 |
| Employees | 2,506 | 910 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 20.3× (better) | 38.8× |
| P/B | – | 2.5× |
| FCF yield | −1.0% (better) | −4.6% |
| Growth | ||
| Revenue growth (TTM) | 42.7% (better) | 23.1% |
| Revenue growth, 5Y average | 27.9% | – |
| Profitability | ||
| Gross margin | 65.0% | – |
| Operating margin | −39.7% (better) | −338% |
| Net margin | −38.3% (better) | −237% |
| FCF margin | −20.3% (better) | −179% |
| Return on equity | – | −16.1% |
| Return on invested capital | – | −26.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −97.6× | – |
| Current ratio | 4.03 | 10.95 (better) |
| Altman Z-score | 4.83 | 7.40 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.8% | 87.6% |
| Held by insiders | 1.9% | 11.2% |
| Insider net buying, 12 months | −$174M | −$111M (better) |
| Short interest, % of float | 9.1% | 20.2% |
Go deeper
- GH stock overview
- GH income statement
- GH valuation and score
- GRAL stock overview
- GRAL income statement
- GRAL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.